Trial Profile
MaasFlex: Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxidation, Glucose Metabolism and Muscle Mitochondrial Function in Individuals With Impaired Glucose Homeostasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Glucose intolerance; Glucose metabolism disorders; Insulin resistance; Prediabetic state
- Focus Pharmacodynamics
- Acronyms MaasFlex
- 01 Mar 2023 Results published in the Metabolism - Clinical and Experimental
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 18 Aug 2021 Status changed from active, no longer recruiting to completed.